Organovo Holdings (ONVO) : Traders are bullish on Organovo Holdings (ONVO) as it has outperformed the S&P 500 by a wide margin of 16.58% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.39%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.44% in the last 1 week, and is up 17.78% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 6.83% and the 50-Day Moving Average is 22.21%. Organovo Holdings (NYSEMKT:ONVO): stock turned positive on Friday. Though the stock opened at $4.58, the bulls momentum made the stock top out at $4.6 level for the day. The stock recorded a low of $4.51 and closed the trading day at $4.57, in the green by 0.66%. The total traded volume for the day was 610,208. The stock had closed at $4.54 in the previous days trading.
The company Insiders own 12.5% of Organovo Holdings shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.75% . Institutional Investors own 19.21% of Organovo Holdings shares. During last six month period, the net percent change held by insiders has seen a change of -2.75%.
Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.